Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) is approved by the U.S. Food and Drug Administration to treat HER2-positive metastatic breast cancer that has previously been treated with Herceptin (chemical name: trastuzumab) and a taxane chemotherapy.
In this section you can learn more about:
- How Kadcyla Works
- Will Kadcyla Work for You?
- What to Expect When Taking Kadcyla
- Kadcyla Side Effects
To connect with others with HER2-positive breast cancer, join the Breastcancer.org Discussion Board HER2-Positive Breast Cancer forum.
Or, to connect with others diagnosed with metastatic breast cancer, join the Breastcancer.org Discussion Board Stage IV and Metastatic Breast Cancer ONLY forum.